Published in Fam Cancer on June 01, 2013
PMS2 monoallelic mutation carriers: the known unknown. Genet Med (2015) 1.44
Lynch syndrome: an updated review. Genes (Basel) (2014) 1.02
The evolution of colorectal cancer genetics-Part 2: clinical implications and applications. J Gastrointest Oncol (2014) 0.86
Considerations and management of a patient with three metachronous cancers in association with Lynch syndrome and ileal Crohn's disease: A case report. Int J Surg Case Rep (2015) 0.82
Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer. DNA Repair (Amst) (2015) 0.82
Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case. Fam Cancer (2015) 0.81
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist (2016) 0.78
New insights into the mechanism of DNA mismatch repair. Chromosoma (2015) 0.78
Recent discoveries in the molecular genetics of Lynch syndrome. Fam Cancer (2016) 0.77
Mechanisms of glycosylase induced genomic instability. PLoS One (2017) 0.75
Novel Mutations in MLH1 and MSH2 Genes in Mexican Patients with Lynch Syndrome. Gastroenterol Res Pract (2016) 0.75
Historical Perspective on Familial Gastric Cancer. Cell Mol Gastroenterol Hepatol (2017) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Microsatellite instability in cancer of the proximal colon. Science (1993) 14.51
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell (1993) 13.54
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Mutation of a mutL homolog in hereditary colon cancer. Science (1994) 9.04
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (1994) 8.04
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet (2000) 5.04
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet (2008) 4.44
Genetic mapping of a locus predisposing to human colorectal cancer. Science (1993) 4.12
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA (2005) 3.99
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res (1994) 3.63
EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med (2009) 3.57
GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science (1995) 3.34
Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet (1997) 3.34
Conversion of diploidy to haploidy. Nature (2000) 3.28
Mutations of GTBP in genetically unstable cells. Science (1995) 3.23
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med (1966) 2.86
MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet (1998) 2.73
Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst (1995) 2.62
Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet (1993) 2.37
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res (1995) 2.17
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer (2003) 2.07
Cancer family "G" revisited: 1895-1970. Cancer (1971) 1.81
Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci U S A (1992) 1.74
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer (1985) 1.51
Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest (1996) 1.49
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer (1985) 1.48
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology (2010) 1.40
Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer (2005) 1.40
FAMILIAL CANCER OF THE COLON. Acta Chir Scand (1964) 1.25
Familial colonic cancer without antecedent polyposis. Ann Intern Med (1984) 1.21
Heredity and adenocarcinoma of the colon. Gastroenterology (1967) 1.17
Heredity and multiple primary malignant neoplasms: six cancer families. Am J Med Sci (1967) 1.04
Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol (2011) 0.97
A family history of uterine and gastro-intestinal cancer. Br Med J (1956) 0.91
History and molecular genetics of Lynch syndrome in family G: a century later. JAMA (2005) 0.88
History of the International Collaborative Group on Hereditary Non Polyposis Colorectal Cancer. Fam Cancer (2003) 0.83
FAMILIAL DISPOSITION OF CANCER OF THE GASTROINTESTINAL TRACT. Acta Chir Scand (1965) 0.76
[Familial incidence of double malignancies]. Schweiz Med Wochenschr (1966) 0.76
[Hereditary nature of cancers of the colon]. Bull Cancer (1970) 0.76
[DOUBLE CANCER IN SIBLINGS. FAMILIAL ASSOCIATION OF CANCER OF THE GENITALIA AND INTESTINES]. Schweiz Med Wochenschr (1965) 0.76
Origins of the Leeds Castle Polyposis Group. Fam Cancer (2003) 0.76
[ON A CANCER FAMILY. A CONTRIBUTION TO THE PROBLEM OF THE HEREDITARY ASPECTS OF COLONIC CARCINOMA]. Helv Chir Acta (1964) 0.76
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Colorectal cancer. Lancet (2010) 8.36
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer (2008) 2.95
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum (2010) 1.88
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet (2003) 1.80
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) (2010) 1.80
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut (2007) 1.68
Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril (2013) 1.62
The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer (2005) 1.57
What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med (2012) 1.54
Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol (2013) 1.52
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol (2005) 1.50
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer (2006) 1.47
Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer (2008) 1.45
MGUS, multiple myeloma, and paratarg-7. Lancet Oncol (2009) 1.39
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer (2003) 1.38
Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer. Breast Cancer Res Treat (2015) 1.37
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer (2008) 1.28
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 1.27
A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev (2005) 1.27
Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer (2004) 1.25
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A (2002) 1.23
Molecular screening for the Lynch syndrome--better than family history? N Engl J Med (2005) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst (2010) 1.21
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control (2005) 1.20
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res (2004) 1.18
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol (2005) 1.16
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat (2013) 1.16
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol (2006) 1.14
Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol (2010) 1.12
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One (2013) 1.10
Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). Arch Intern Med (2004) 1.10
Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2012) 1.10
Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study. Int J Colorectal Dis (2002) 1.09
Origins and prevalence of the American Founder Mutation of MSH2. Cancer Res (2008) 1.06
The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer (2011) 1.06
Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol (2006) 1.06
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res (2011) 1.05
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res (2009) 1.04
Hereditary nonpolyposis colorectal cancer: preventive management. Cancer Treat Rev (2003) 1.02
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 1.01
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer (2007) 1.01
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res (2009) 1.01
Pathogenicity of the hereditary colorectal cancer mutation hMLH1 del616 linked to shortage of the functional protein. Gastroenterology (2003) 0.99
Screening adherence in BRCA1/2 families is associated with primary physicians' behavior. Am J Med Genet A (2004) 0.99
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol (2013) 0.98
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer (2009) 0.98
The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev (2007) 0.98
Hereditary colorectal cancer-part II. Curr Probl Surg (2005) 0.98
Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol (2004) 0.97
Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome. Int J Surg Pathol (2010) 0.97
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest (2008) 0.96
Hereditary colon cancer--part I. Curr Probl Surg (2005) 0.96
Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control (2008) 0.95
Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome). J Natl Cancer Inst (2007) 0.95
Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2005) 0.95
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis (2005) 0.94
Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer (2003) 0.94
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat (2010) 0.93
Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol (2012) 0.93
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat (2014) 0.93
PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform (2011) 0.92
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2011) 0.92
Hereditary pancreatic cancer: a clinical perspective. Best Pract Res Clin Gastroenterol (2009) 0.92
Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. Int J Cancer (2005) 0.91
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol (2005) 0.91
Risk of colon cancer in hereditary non-polyposis colorectal cancer patients as predicted by fuzzy modeling: Influence of smoking. World J Gastroenterol (2006) 0.91
Inherited, familial and sporadic primary open-angle glaucoma. J Natl Med Assoc (2007) 0.89
Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer (2003) 0.89